Canada Markets closed

Valneva SE (VLA.VI)

Vienna - Vienna Delayed Price. Currency in EUR
Add to watchlist
10.16+0.43 (+4.46%)
At close: 05:07PM CEST
Full screen
Previous Close9.73
Open11.80
Bid10.16 x 50000
Ask10.31 x 81200
Day's Range9.52 - 10.28
52 Week Range2.06 - 10.28
Volume5,072
Avg. Volume14,123
Market Cap915.277M
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Valneva Receives Notice of European Commission’s Intent to Terminate COVID-19 Vaccine Purchase Agreement

    Saint-Herblain (France), May 16, 2022 – Valneva SE, a specialty vaccine company, today announced that it has received a notice from the European Commission (“EC”) of intent to terminate the advance purchase agreement (“APA”) for Valneva’s inactivated whole-virus COVID-19 vaccine candidate VLA2001. The APA provides the EC with a right to terminate the APA if VLA2001 had not received a marketing authorization from the European Medicines Agency (“EMA”) by April 30, 2022. Based on the terms of the A

  • GlobeNewswire

    Valneva Receives Emergency Use Authorization from the United Arab Emirates for its Inactivated COVID-19 Vaccine

    Saint Herblain (France), May 16, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United Arab Emirates (UAE) granted emergency use authorization for Valneva’s inactivated, adjuvanted COVID-19 vaccine, VLA2001. Thomas Lingelbach, Chief Executive Officer of Valneva, commented, “We are extremely pleased with this new authorization and would like to thank the UAE for their trust and confidence. As the only dual-adjuvanted, whole-virus inact

  • GlobeNewswire

    Valneva Reports Q1 2022 Results and Provides Corporate Updates

    Excellent progress on clinical programs Lyme Disease Vaccine Candidate VLA15 Further positive Phase 2 results reported, including first pediatric data Phase 3 expected to commence in the third quarter of 2022 Inactivated COVID-19 Vaccine Candidate VLA2001 Conditional Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK)Emergency use authorization granted by the National Health Regulatory Authority (NHRA) of the Kingdom of Bah